Stock 600062 CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings China Resources Double-Crane Pharmaceutical Co.,Ltd.

Equities

600062

CNE000000Q94

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
21.2 CNY -0.84% Intraday chart for China Resources Double-Crane Pharmaceutical Co.,Ltd. +0.66% +13.98%
Apr. 26 CR Double-Crane Pharmaceutical's Profit Rises 11% in Q1 as Revenue Grows 2% MT
Apr. 26 CR Double-Crane Pharmaceutical's Unit Gets Nod to Trial New Pain Medication MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The group's high margin levels account for strong profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company is not the most generous with respect to shareholders' compensation.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. Stock China Resources Double-Crane Pharmaceutical Co.,Ltd.
+13.98% 2.99B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
B+
NOVARTIS AG Stock Novartis AG
+5.46% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
A+
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600062 Stock
  4. Ratings China Resources Double-Crane Pharmaceutical Co.,Ltd.